Moleculin Biotech, Inc. (MBRX) Stock Score, Valuation & Financial Research

Moleculin Biotech, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for MBRX

Moleculin Biotech, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 0.45. These figures are a research snapshot, not a buy or sell recommendation.

What Moleculin Biotech, Inc. does

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Moleculin Biotech is a clinical-stage pharmaceutical company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and other financing activities to fund the research, development, and clinical trials of its proprietary drug candidates targeting hard-to-treat cancers and viruses.

Products and services

  • The company's primary product candidates include Annamycin, a next-generation anthracycline, and other preclinical compounds targeting cancer and viral indications.

Business relationships and partnerships

  • AnnaMed, Inc. — The company maintains a Rights Transfer Agreement with AnnaMed, Inc. regarding its drug development assets. Source

Business strengths to evaluate

  • Proprietary portfolio of drug candidates targeting hard-to-treat cancers and viruses Source

Business risks and research considerations

  • History of operating losses and dependence on future financing to continue operations Source
  • Uncertainty regarding the success of clinical trials and regulatory approval processes Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

MBRX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.45
Market capitalization:
2.38M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -30.33M
Free cash flow:
USD -22.74M
Cash:
USD 7.26M
Total debt:
USD 292K
EPS:
USD -17.13

What stands out

  • Free cash flow is USD -22.74M, negative for the stored period.
  • The balance sheet shows USD 7.26M of cash versus USD 292K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 6.97M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for MBRX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can MBRX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is MBRX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for MBRX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of MBRX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-05.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research MBRX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.